Premium
Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastics and malignant human prostatic epithelium
Author(s) -
Sharpe J.C.,
Abel P.D.,
Gilbertston J.A.,
Brawn P.,
Foster C.S.
Publication year - 1994
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1994.tb09193.x
Subject(s) - mhc class i , major histocompatibility complex , mhc class ii , lymph node , biology , pathology , immunohistochemistry , antigen processing , antigen , immunology , medicine
Objectives To determine whether human prostatic carcinoma cells express Class I and/or Class II major histocompatibility complex (MHC) determinants and whether they might thus be immune‐competent targets for cell‐mediated cytotoxicity Materials and methods Immunohistochemistry, performed both before and after neuraminidase digestion. wass employed to compare 13 benign prostatic hyperplaisia with 42 primary and 44 metastatic prostatic carcinomas obtained from the United Kingdom and from the United States of America. Expression of β 2 microglopbulin was used as the marker of Class I and HLA‐DR as the marker of Class II expression. Results Before desialylation. Class I MHC determinants were expressed in all of the benign hyperplasias in 26% of primary carcinomas and in 14% of lymoh node meatastases. Cells expressing Class I determinants were identified in 69% of benign hyperplasias and in 2% of primary carcnomas, but in none of the lymph node metastatses. After deisalylation. Class I deternants were expressed in 100% of benign hyperplasias 59% of primary carcinomas and 34% of the lymph node meatastases. Class II determinants were identified in were expressed in 100% of benign hyperplasias. but only 19% of primary carcinomas and 5% of epithelial cells in each of the benign hyperplasias expressed MHCs, <% of the tumour cell poplulations in the positive malignant tissues (primary and metastatic)expressed MHCs, even after neuraminidase digestion. No correlation was found between expression of Class I or Class II MHC and Gleason morphological grade. Conclusions Failure to express Class I and/or Class II MHC determinants is a common feature of the majority of human prostatic carcinoma cells. Absence of these recognition moleculed may be associate with avoidance of immune‐surveillance and contribute to the metastatic dissemination of this malignancey.